Volcano Corporation Announces Agreement To Acquire Crux Biomedical

Volcano Corporation has signed an agreement to acquire Crux Biomedical, a privately-held company that has developed a highly differentiated inferior vena cava (IVC) filter—the Crux VCF System—to treat pulmonary embolisms (PE’s).



Volcano Corporation Announces Agreement To Acquire Crux Biomedical (via PR Newswire)

SAN DIEGO, Dec. 3, 2012 /PRNewswire/ — Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today it has signed an agreement to acquire Crux Biomedical…



published: December 3, 2012 in: Cardio, Mergers and Acquisitions, Thoracic/Respiratory

Most read

Latest

^